Sugi Predict

Sugi Predict / Compounds / SCHEMBL381600

SCHEMBL381600

SCHEMBL381600

O=C(O)c1ccc2nc(Br)sc2c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 5/20 0.64
▸ KDM4E B2RXH2 4/20 0.64
▸ NFKB1 P19838 3/20 0.64
▸ NFKB2 Q00653 3/20 0.64
▸ RELA Q04206 3/20 0.64
▸ LMNA P02545 2/20 0.64
▸ NPC1 O15118 8/20 0.59
▸ RAB9A P51151 8/20 0.59
▸ TDP1 Q9NUW8 3/20 0.59
▸ ALDH1A1 P00352 3/20 0.59
▸ HPGD P15428 3/20 0.59
▸ MITF O75030 2/20 0.59
▸ GAA P10253 2/20 0.59
▸ POLB P06746 1/20 0.59
▸ MAPT P10636 1/20 0.59
▸ RECQL P46063 1/20 0.59
▸ GFER P55789 1/20 0.59
▸ PAX8 Q06710 1/20 0.59
▸ KLF5 Q13887 1/20 0.59
▸ HKDC1 Q2TB90 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30063475 0.86 NPC1 (0.70) SMN1; SMN2KDM4ENFKB1NFKB2RELA
SCHEMBL25252536 0.86 NPC1 (0.70) SMN1; SMN2KDM4ENFKB1NFKB2RELA
SCHEMBL121976 0.84 RAB9A (0.52) SMN1; SMN2KDM4ENFKB1NFKB2RELA
SCHEMBL30017067 0.84 DYRK1A (0.60) SMN1; SMN2KDM4ENFKB1NFKB2RELA
SCHEMBL18984451 0.82 SMN1; SMN2 (0.64) SMN1; SMN2KDM4ENFKB1NFKB2RELA
SCHEMBL1261509 0.82 NPC1 (0.75) SMN1; SMN2KDM4ENFKB1NFKB2RELA
SCHEMBL22849991 0.81 SMN1; SMN2 (0.59) SMN1; SMN2KDM4ENFKB1NFKB2RELA
SCHEMBL1036069 0.81 KDM4E (0.62) SMN1; SMN2KDM4ENFKB1NFKB2RELA
SCHEMBL22924402 0.81 SMN1; SMN2 (0.62) SMN1; SMN2KDM4ENFKB1NFKB2RELA
SCHEMBL6267261 0.81 SMN1; SMN2 (0.62) SMN1; SMN2KDM4ENFKB1NFKB2RELA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240150339-A1 Compounds and Their Use as PDE4 Activators MIRONID LIMITED (GB) 2024-05-09 — — US disclosed
WO-2024006956-A9 DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2024-04-11 — — WO disclosed
CN-112105604-B Novel compounds exhibiting intestinal peptidase inhibitory activity 株式会社LG化学 2024-01-09 — — CN disclosed
WO-2024006956-A2 DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2024-01-04 — — WO disclosed
EP-4291557-A1 COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS Mironid Limited (GB) 2023-12-20 — — EP disclosed
CN-116848107-A Compounds and their use as PDE4 activators 米罗尼德有限公司 2023-10-03 — — CN disclosed
EP-3778577-B1 NOVEL COMPOUND EXHIBITING ENTEROPEPTIDASE INHIBITORY ACTIVITY LG CHEMICAL LTD (KR) 2023-08-30 — — EP disclosed
US-11447480-B2 Compound exhibiting enteropeptidase inhibitory activity LG CHEM, LTD. (KR) 2022-09-20 — — US disclosed
WO-2022172037-A1 COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS MIRONID LIMITED (GB) 2022-08-18 — — WO disclosed
US-20210284634-A1 NOVEL COMPOUND EXHIBITING ENTEROPEPTIDASE INHIBITORY ACTIVITY LG CHEM, LTD. (KR) 2021-09-16 — — US disclosed
US-20120071467-A1 AMIDE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-03-22 — — US disclosed
EP-2409977-A1 AMIDE DERIVATIVE Daiichi Sankyo Company, Limited (JP) 2012-01-25 — — EP disclosed
US-20110152287-A1 SUBSTITUTED BENZOTHIAZOLE AND BENZOXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF DPP-1 JANSSEN PHARMACEUTICA NV (BE) 2011-06-23 — — US disclosed
WO-2011075631-A1 SUBSTITUTED BENZOTHIAZOLE AND BENZOXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF DPP-1 JANSSEN PHARMACEUTICA NV (BE) 2011-06-23 — — WO disclosed
CN-101410393-A Novel heteroaryl substituted benzothiazoles ASTRAZENECA AB (SE) 2009-04-15 — — CN disclosed
US-20090028787-A1 Novel Heteroaryl Substituted Benzothiazoles NAVIDEA BIOPHARMACEUTICALS, INC. 2009-01-29 — — US disclosed
EP-1981883-A1 NOVEL HETEROARYL SUBSTITUTED BENZOTHIAZOLES AstraZeneca AB (SE) 2008-10-22 — — EP disclosed
WO-2008124393-A1 BENZOTHIAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2008-10-16 — — WO disclosed
WO-2008124393-A1 BENZOTHIAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2008-10-16 — — WO disclosed
WO-2007086800-A1 NOVEL HETEROARYL SUBSTITUTED BENZOTHIAZOLES ASTRAZENECA AB (SE) 2007-08-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210284634-A1 NOVEL COMPOUND EXHIBITING ENTEROPEPTIDASE INHIBITORY ACTIVITY TMPRSS15, DPP9, LIPC SMN1; SMN2 4591/4885KDM4E 2854/4885NFKB1 2306/4885
US-20090028787-A1 Novel Heteroaryl Substituted Benzothiazoles APP, MAPT, PSEN1 SMN1; SMN2 1164/4885KDM4E 2091/4885NFKB1 2453/4885
US-11447480-B2 Compound exhibiting enteropeptidase inhibitory activity TMPRSS15, DPP9, DPP4 SMN1; SMN2 4587/4885KDM4E 2660/4885NFKB1 2275/4885
US-20110152287-A1 SUBSTITUTED BENZOTHIAZOLE AND BENZOXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF DPP-1 DPP4, DPP7, DPP3 SMN1; SMN2 2786/4885KDM4E 1638/4885NFKB1 2758/4885
US-20120071467-A1 AMIDE DERIVATIVE CHRM3, CHRM2, TACR2 SMN1; SMN2 1907/4885KDM4E 1529/4885NFKB1 2099/4885
US-20240150339-A1 Compounds and Their Use as PDE4 Activators PDE4A, PDE4B, PDE4C SMN1; SMN2 1885/4885KDM4E 1809/4885NFKB1 2652/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.